Avenue Therapeutics Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Avenue Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATXI, but not buy additional shares or sell existing shares.
View analyst ratings for Avenue Therapeutics or view top-rated stocks.

Wall Street analysts have given Avenue Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Avenue Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Avenue Therapeutics.

Avenue Therapeutics, Inc. (NASDAQ:ATXI) announced its quarterly earnings data on Tuesday, March, 30th. The company reported ($0.06) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.06).
View Avenue Therapeutics' earnings history.

Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATXI shares have decreased by 7.8% and is now trading at $6.86.
View which stocks have been most impacted by COVID-19.

1 analysts have issued 1 year price targets for Avenue Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Avenue Therapeutics' share price to reach $6.00 in the next year. This suggests that the stock has a possible downside of 12.5%.
View analysts' price targets for Avenue Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Avenue Therapeutics include Atreca (BCEL), Foghorn Therapeutics (FHTX), Catalyst Pharmaceuticals (CPRX), Inozyme Pharma (INZY), Applied Therapeutics (APLT), Viking Therapeutics (VKTX), XOMA (XOMA), Sesen Bio (SESN), Seelos Therapeutics (SEEL), DURECT (DRRX), Nabriva Therapeutics (NBRV), Oncternal Therapeutics (ONCT), Flexion Therapeutics (FLXN), BeyondSpring (BYSI) and Syros Pharmaceuticals (SYRS).
View all of ATXI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include Gilead Sciences (GILD), AbbVie (ABBV), Fulcrum Therapeutics (FULC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Allena Pharmaceuticals (ALNA), Actinium Pharmaceuticals (ATNM), CymaBay Therapeutics (CBAY), CytomX Therapeutics (CTMX) and Spero Therapeutics (SPRO).

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATXI stock can currently be purchased for approximately $6.86.

Avenue Therapeutics has a market capitalization of $114.89 million. The company earns $-25,910,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

Avenue Therapeutics employs 4 workers across the globe.

The official website for Avenue Therapeutics is www.avenuetx.com.

Avenue Therapeutics is headquartered at 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036.

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The company can be reached via phone at 781-652-4500 or via email at [email protected]